Can-Fite BioPharma Ltd. (CANF) SEC filings

CANFNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026Score 1/30

$1.42−0.07 (-4.70%)

Close on Nov 13, 2026Market cap $1.86MP/E –Yield –

SEC filings

40 of Can-Fite BioPharma's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Current report	6-K	Nov 9, 2026	Nov 9, 2026	SEC EDGAR
Current report	6-K	Nov 2, 2026	Nov 2, 2026	SEC EDGAR
Current report	6-K	Oct 26, 2026	Oct 26, 2026	SEC EDGAR
Current report	6-K	Sep 9, 2026	Sep 9, 2026	SEC EDGAR
Current report	6-K	Jun 30, 2026	Sep 8, 2026	SEC EDGAR
Current report	6-K	Sep 3, 2026	Sep 3, 2026	SEC EDGAR
Current report	6-K	Sep 2, 2026	Sep 2, 2026	SEC EDGAR
Current report	6-K	Sep 2, 2026	Sep 2, 2026	SEC EDGAR
Current report	6-K	Aug 17, 2026	Aug 17, 2026	SEC EDGAR
Current report	6-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Current report	6-K	Aug 3, 2026	Aug 3, 2026	SEC EDGAR
Current report	6-K	Jul 20, 2026	Jul 20, 2026	SEC EDGAR
Current report	6-K	Jul 14, 2026	Jul 14, 2026	SEC EDGAR
Current report	6-K	Jul 6, 2026	Jul 6, 2026	SEC EDGAR
Current report	6-K	Jul 1, 2026	Jul 1, 2026	SEC EDGAR
Current report	6-K	Jun 26, 2026	Jun 26, 2026	SEC EDGAR
Current report	6-K	Jun 22, 2026	Jun 22, 2026	SEC EDGAR
Current report	6-K	Jun 17, 2026	Jun 17, 2026	SEC EDGAR
Current report	6-K	Jun 4, 2026	Jun 4, 2026	SEC EDGAR
Current report	6-K	Jun 2, 2026	Jun 2, 2026	SEC EDGAR
Current report	6-K	May 28, 2026	May 28, 2026	SEC EDGAR
Current report	6-K	May 18, 2026	May 18, 2026	SEC EDGAR
Current report	6-K	May 13, 2026	May 13, 2026	SEC EDGAR
Current report	6-K	Apr 30, 2026	Apr 30, 2026	SEC EDGAR
Current report	6-K	Apr 23, 2026	Apr 23, 2026	SEC EDGAR
Current report	6-K	Mar 30, 2026	Mar 30, 2026	SEC EDGAR
Annual report	20-F	Dec 31, 2025	Mar 26, 2026	SEC EDGAR
Current report	6-K	Mar 26, 2026	Mar 26, 2026	SEC EDGAR
Current report	6-K	Mar 17, 2026	Mar 17, 2026	SEC EDGAR
Current report	6-K	Mar 10, 2026	Mar 10, 2026	SEC EDGAR
Current report	6-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	6-K	Mar 4, 2026	Mar 4, 2026	SEC EDGAR
Current report	6-K	Mar 3, 2026	Mar 3, 2026	SEC EDGAR
Current report	6-K	Feb 17, 2026	Feb 17, 2026	SEC EDGAR
Current report	6-K	Feb 9, 2026	Feb 9, 2026	SEC EDGAR
Current report	6-K	Feb 5, 2026	Feb 5, 2026	SEC EDGAR
Current report	6-K	Jan 27, 2026	Jan 27, 2026	SEC EDGAR
Current report	6-K	Jan 20, 2026	Jan 20, 2026	SEC EDGAR
Current report	6-K	Jan 16, 2026	Jan 16, 2026	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Can-Fite BioPharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-3000 reverse split on Mar 26, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CANF.

Compare: CANF vs XTLB · CANF vs LIPO · CANF vs SCNX · CANF vs RLYB · CANF vs RDHL

Revenue growth-39.9% · median -27.5%

Operating margin-2456.8% · median -3484.4%

Net margin-2426.7% · median 2405.0%

Company	Revenue	Growth
RLYB	$434.00K	-35.6%
CANF	$405.00K	-39.9%
LIPO	$389.78K	-19.4%
XTLB	–	–
SCNX	–	–
RDHL	–	–

Company

Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 5
Held by institutions: 1.9%
Auditor: KOST FORER GABBAY& KASIERER
SEC CIK: 1536196

Advertisement
300 × 250

See a number that looks wrong?